Psychopharmacological properties of Ptychopetalum olacoides Bentham (olacaceae)

Pharmaceutical Biology

Volumn 36, Issue 5, 1998, Pages 327-334

  Siqueira, I R ^a   Lara, D R ^a   Silva, D ^a   Gaieski, F S ^a   Nunes, D S ^b   Elisabetsky, Elaine ^a,c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF PARÁ   (Brazil)

^c NONE   (Brazil)

Author keywords

Dopamine; Noradrenaline; Ptychopetalum olacoides; Serotonin; Tonics

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CENTRAL NERVOUS SYSTEM AGENTS; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; NORADRENALIN; PLANT EXTRACT; SEROTONIN; YOHIMBINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOPAMINERGIC SYSTEM; ETHNOPHARMACOLOGY; IMPOTENCE; INTRAPERITONEAL DRUG ADMINISTRATION; LASSITUDE; LETHALITY; MALE; MOUSE; NONHUMAN; NORADRENERGIC SYSTEM; PSYCHOPHARMACOLOGY; PTOSIS; SEROTONINERGIC SYSTEM; SEXUAL AROUSAL; STEREOTYPY; TREMOR;

EID: 0032311123     PISSN: 13880209     EISSN: None     Source Type: Journal    
DOI: 10.1076/phbi.36.5.327.4657     Document Type: Article

References (43)

1. Ahmed A, Marshall BB (1962): Relationship between anti acetylcholine and antitremorine activity in anti-Parkinsonian and related drugs. Br J Pharmacol 18: 247-254.
2. Bandoni AL, Mendiondo ME, Rondina RVD, Coussio JD (1972): Survey of Argentine medicinal plants - folklore and phytochemical screening. Lloydia 35: 69-80.
3. Birkmayer W, Riederer P (1983): Parkinson's disease: biochemistry, clinical pathology, and treatment. Springer-Verlag, New York.
4. Blier P, Montigny C (1994): Current advances and trends in the treatment of depression. Trends Pharmacol Sc 15: 220-226.
5. Bourin M, Poncelet M, Chermat R, Simon P (1983): The Value of the Reserpine Test in Psychopharmacology. Drug Res 33: 1173-1176.
6. Bourin M, Poisson L, Larousse C (1986): Piracetam interaction with neuroleptics in psychopharmacological tests. Neuropsychobiology 19: 93-96.
7. Buffun J (1982): Pharmacosexology: the effects of drugs on sexual function. J Psychoactive Drugs 14: 5-41.
8. Campanella G et al. (1987): drugs affecting movement disorders. Ann Rev Pharmacol Toxicol 27: 113-136.
9. Costa AF (1972): Farmacognosia. vol 3. Fund. Calouste Gulbenkian, Lisboa.
10. Dandiya PC, Menon MK (1965): Interaction of asarone with mescaline, amphetamine and tremorine. Life Sci 4: 1635-1641.
11. DeFeudis FV (1991): In vivo studies with Egb 761. In: Ginkgo biloba Extract (EGb 761): Pharmacological Activities and Clinical Applications, 61-96 pp., Elsevier, Paris.
12. Dickinson SL, Curzon G (1983): Roles of dopamine and 5-hydroxytryptamine in stereotyped and non-stereotyped behaviour. Neuropharmacology 22: 805-812.
13. 2-adrenoceptor antagonists differentially inflence locomotor and stereotyped behaviour induced by d-amphetamine and apomorphine in the rat. Psychopharmacology 96: 521-527.
14. Duke JA (1992a): Handbook of Phytochemical Constituents of GRAS Herbs and Other Economic Plants. CRC Press, Boca Raton, FL.
15. Duke JA (1992b): Handbook of biologically active phytochemicals and their activities. CRC Press, Boca Raton, FL.
16. Elisabetsky E (1987): From indigenous disease concepts to laboratory work hypothesis: The case of "nerve tonics" from the Brazilian Amazon. International Foundation for Science, Provisional Report Series, IFS, Grev Turegatan 19, S-11438, Stockholm, Sweden.
17. Elisabetsky E, Setzer R (1985): Caboclo concepts of disease diagnosis and therapy: implications for ethnopharmacology and health systems in Amazonia. In: Parker EP, eds., The Amazon Caboclo: historical and contemporary perspectives 32: 243-278, Williamsburgh: Studies on Third World Societies Publication Series.
18. Elisabetsky E, Figueiredo W, Oliveira G (1992): Traditional Amazonian nerve tonics as antidepressant agents: Chaunochiton kappleri: a case study. J Herbs Spices, Med Plants 1: 125-161.
19. Ellenbroek BA (1993): Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacol & Therapeut 57: 1-78.
20. Fibiger HC (1984): The neurobiological substrates of depression in Parkinson's disease: a hypothesis. Can J Neurolog Sc 11: 105-107.
21. 2-like" receptor family. Neurotransmissions 11: 1-5.
22. Forgacs P, Jacquemin H, Moretti C, Provost J, Touche A (1983): Phytochemical and biological activity studies on 18 plants from French Guyana. Plant Méd Phytothér 17: 22-32.
23. Grenand P, Moretti C, Jacquemin H (1987): Pharmacopées traditionnelles en Guyane. Editions de L'Orstom, France.
24. Holohean AH, White FJ, Appel JB (1982): Dopaminergic and serotoninergic mediation of the discriminable effects of ergot alkaloids. Eur J Pharmacol 81: 595-602.
25. Hyman SE, Nestler EJ (1996): Initiation and adaptation: a paradigm for understanding psychotropic drug action. Amer J Psych 152: 151-162.
26. Jackson DM, Westlind-Danielsson A (1994): Dopamine receptors: molecular biology, biochemistry and behavioural aspects. Pharmacol Therap 64: 291-369.
27. Le Moal M (1995): Mesocorticolimbic dopaminergic neurons: functional and regulatory roles. In: Bloom F, Kupfer DJ, eds., Psychopharmacology: the fourth generation of progress. New York, Raven Press, pp. 283-293.
28. Leonard BE (1986): Mechanism of action of antidepressants: relevance to understanding the psychobiology of depression? Clin Neuropharmacol 9: 67-69.
29. Malick JB (1983): Potentiation of Yohimbine-induced lethality in mice: predictor of antidepressant potential. Drug Dev Res 3: 357-363.
30. Malone MH (1983): The pharmacological evaluation of natural products - general and specific approaches to screening ethnopharmaceuticals. J Ethnopharmacol 8: 127-147.
31. Männistö PT et al. (1995): Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylanine in rat models of depression. Eur J Pharmacol 274: 229-233.
32. Matos FSA (1988): Introdução à Fitoquímica Experimental, 126 pp., Ed. Universidade Federal do Ceará, Fortaleza.
33. Nakachi et al. (1995): Effects of various dopamine uptake inhibitors on striatal extracellular dopamine levels and behaviours in rats. Eur J Pharmacol 281: 195-203.
34. Oates JA (1996): Antihypertensive agents and drug therapy of hypertension. In: Goodman LS, Gilman A, and Gilman, AG, eds., Pharmacological basis of therapeutics, New York, Pergamon, pp. 781-808.
35. Polansky J, Prangé T, Pascard C (1984): Structure (X-ray analysis) of manicoline B, a mixture of two diastereoisomers of a new alkaloid from Dulacia guianensis (Olacaceae). Tetrahedron Letters 25: 2359-2362.
36. Quiton RM (1963): The increase in the toxicity induced by imipramine and other drugs in mice. Brit J Pharmacol Chemother 21: 51-66.
37. Sleumer HO (1984): Flora Neotropica, The New York Botanical Garden, New York, 159pp.
38. Steinmetz EF (1962): Muira puama ("potency wood"). Quart J Crude Drug Res 2: 229-232.
39. Uber Bucek E, Fournier G, Dadoun H (1987): Volatile constituents of Ptychopetalum olacoides root oil. Planta Med 53: 231.
40. Waddington JL, Gamble SJ (1980): Differential effect of ageing on distinct features of apomorphine stereotypy in the adult rat. Neuroscience Letters 20: 95-99.
41. Wagner H, Nörr H, Winterhoff H (1994): Plant Adaptogens, Phytomedicine 1: 63-76.
42. Willner P (1984): The validity of animal models of depression. Psychopharmacol 83: 1-16.
43. Willner P (1990): Animal models of depression: an overview. Pharmacol Therap 45: 425-455.